Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study [Hematologic Malignancy]

Conclusion
In this phase I study of relapsed/refractory NHL, continuous infusion with CD19-targeted immunotherapy blinatumomab at various doses and schedules was feasible, with an MTD of 60 μg/m2/day. Single-agent blinatumomab showed antilymphoma activity.

Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Goebeler, Knop, Viardot, Kufer, Topp, Einsele, Noppeney, Hess, Kallert, Mackensen, Rupertus, Kanz, Libicher, Nagorsen, Zugmaier, Klinger, Wolf, Dorsch, Quednau, Schmidt, Scheele, Baeuerle, Leo, Bargou Tags: Clinical Trials, Phase I and Clinical Pharmacology, Translational Oncology, Hematologic Hematologic Malignancy Source Type: research